Format

Send to

Choose Destination
Health Aff (Millwood). 2006 Sep-Oct;25(5):1260-9.

Biotechnology and Medicare's new technology policy: lessons from three case studies.

Author information

1
Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine in New Haven, Connecticut, USA. patricia.keenan@yale.edu

Abstract

Biotechnology has figured prominently in recent Medicare coverage and payment policies. Biotech treatments push policy boundaries for several reasons: They attract strong patient demand; they often treat rare or life-threatening diseases; they may have uncertain evidence of health benefits; and they are often costly. This paper considers case studies of Medicare coverage for off-label uses of biotech cancer drugs and payments for anemia biopharmaceuticals. The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments.

PMID:
16966721
DOI:
10.1377/hlthaff.25.5.1260
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center